Record Quarterly Revenue and Strong YoY Growth
Total revenue of $12.1M in Q1 2026 vs $8.5M in Q1 2025, representing 43% year-over-year growth; management also reported 16% organic growth and device-organic growth of 25%.
ClearPoint Neuro
· CLPT
May 13th, 2026
Summary
- Earnings Call Date:
- 2026-05-13
- Change Since:
- +47.50%
- Next Earnings Date:
- 2026-08-11
Earnings Call Sentiment
PositiveThe call presented a predominantly positive commercial and strategic update: record Q1 revenue (+43% YoY), improved gross margin (64%), significant product and regulatory milestones (PRISM expansion, Velocity drill FDA clearance and CE marking), and visible IRRAflow integration progress and synergies. These positives are tempered by meaningful near-term cash reduction and a $8M operational burn in Q1 plus elevated operating expenses (R&D +34%, S&M +75%, G&A +22%) largely tied to growth investments and integration. Management forecasts a return to improved cash consumption as integration completes and reiterated full-year revenue guidance of $52M–$56M. Regulatory uncertainty on the biologics side and temporary OUS distribution transitions introduce timing risk for some programs, while biologics/drug delivery revenue remained essentially flat (+2%) this quarter. Overall, the fundamentals and strategic momentum outweigh the near-term financial and operational headwinds.
Company Guidance
ClearPoint reiterated 2026 revenue guidance of $52–$56 million, citing a strong start with Q1 record revenue of $12.1 million (up 43% YoY; 16% organic growth; organic devices +25%), gross margin of 64% (vs 60% in Q1 2025), and cash of $35.6 million as of 3/31/26 (down from $45.9M due to $8M operational cash burn in Q1 plus ~$2M tax payments); management expects sequential quarter-over-quarter revenue growth for the year, double-digit growth across each of the four pillars in 2026, the IRRAflow business to represent roughly 20–25% of revenue by year-end and potentially be cash neutral as early as 2027, the site base to grow from >175 active sites today to >200 by end of 2026, and operational cash burn to decrease as IRRAS integration completes.
Capital Equipment and Software Surge
Capital equipment and software revenue rose 177% to $1.4M in Q1 2026 from $0.5M in Q1 2025, driven by increased placements of ClearPoint Navigation Systems, PRISM laser units and IRRAflow control units.
Improved Gross Margin
Gross margin expanded to 64% in Q1 2026, up 4 percentage points from 60% in Q1 2025, primarily due to a decrease in excess and obsolete inventory reserves.
IRRAflow Acquisition Driving Scale and Synergies
IRRAflow contributed to company-wide growth (including $2.1M in IRRAflow disposable revenue in Q1), management reported most post-merger integration costs are behind them and expects meaningful revenue and cost synergies with potential cash neutrality of the IRRAflow addition as early as 2027.
Expanding Commercial Footprint and Partner Network
More than 175 active sites using ClearPoint technology (targeting >200 by end of 2026), over 60 active biopharma partners, 25+ clinical trials across 15+ indications, and more than 10 partner programs under some form of FDA expedited review.
Regulatory and Product Milestones
FDA clearance (U.S.) and CE marking (Europe) received for the Velocity Alpha MR high-speed surgical drill; full market release of PRISM Laser System and iCT solution; first 3.x platform case in Europe and anticipated first Canadian clinical cases.
Guidance and Forward Outlook
Management reaffirmed 2026 revenue guidance of $52M–$56M and noted Q1 cash burn came in on budget; expect all four core business pillars to grow double digits in 2026 (excluding future commercial cell & gene therapy revenue).
Operator
Greetings, and welcome to the ClearPoint Neuro, Inc. First Quarter 2026 Financial Results. [Operator Instructions] As a reminder, this conference is being recorded. Comments made on this call may include statements that are forward-looking within the meaning of securities laws. These forward-looking statements may include, without limitation, statements related to anticipated industry trends, the company's plans, prospects and strategies, both preliminary and projected. Besides the total addressable markets or the market opportunity for the company's products and services; the company's expectations regarding the integration, performance and anticipated benefits of its recent acquisition of IRRAS Holdings, Inc. including operational efficiencies and the impact on the company's financial condition and results of operations. The company's expectation for future development, regulatory approval, timing, commercialization and the market for cell and gene therapies and the anticipated adoption of the company's products and services for use in the delivery of gene and cell therapies, and management's expectations, beliefs, estimates or projections regarding future revenue and results of operations.
You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Actual results or trends could differ materially. The company undertakes no obligation to revise forward-looking statements for new information or future events. For more information about the company's risks and uncertainties, please refer to the compa...
Subscribe to unlock transcripts
Get The Fly Pro 7 days for free